Brought to you by 
Celgene to work on GlobeImmune's cancer candidates
16 Nov 2021
Executive Summary
GlobeImmune (cancer and infectious disease therapeutics) has granted oncology company Celgene options to exclusively develop and commercialize its cancer programs worldwide.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
- Immuno-Oncology
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Includes Equity
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Celgene to work on GlobeImmune's cancer candidates
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice